Literature DB >> 474572

Heparin-induced thrombocytopenia: association with a platelet aggregating factor and arterial thromboses.

P L Cimo, J L Moake, R S Weinger, Y B Ben-Menachem, K G Khalil.   

Abstract

Eleven patients with heparin-induced thrombocytopenia were studied. Thrombocytopenia appeared 3-16 days following the initiation of prophylactic or therapeutic doses of heparin. The mean lowest platelet count recorded was 48,000/mm3. When heparin was stopped, recovery from thrombocytopenia began within 24 hours and was complete by ten days. Two patients developed fatal thromboses, and two others had myocardial infarctions while thrombo-cytopenic. In the serum of seven patients, including three of the four with arterial thrombosis, a heparin-dependent platelet aggregating factor was present. The factor caused release of platelet 14C serotonin but did not lyse platelets. It was present in the globulin fraction of all positive sera, and in one serum studied it was isolated in the IgG/IgA immunoglobulin fraction. The factor was not present in 16 normal sera or in the sera of 15 nonthrombocytopenic patients receiving heparin. Our observations suggest that heparin-induced thrombocytopenia is common and that, in some patients it may be accompanied by severe arterial thrombosis. In vivo platelet aggregation is a possible explanation for the thrombocytopenia and the thrombosis in this disorder.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 474572     DOI: 10.1002/ajh.2830060204

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  13 in total

Review 1.  Perspectives on the long term management of heparin-induced thrombocytopenia.

Authors:  D Brieger
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

2.  Refractoriness to platelet transfusion in acute myeloid leukemia correlated with the optical density of anti-platelet factor 4/heparin antibodies.

Authors:  Mizuki Aimoto; Takahisa Yamane; Kazumasa Shiomoto; Chikahiko Sakamoto; Yasuhiro Nakashima; Hideo Koh; Takahiko Nakane; Yasunobu Takeoka; Asao Hirose; Mika Nakamae; Kiyoyuki Hagihara; Yoshiki Terada; Yoshitaka Nakao; Hirohisa Nakamae; Masayuki Hino; Shigeki Miyata
Journal:  Int J Hematol       Date:  2013-10       Impact factor: 2.490

3.  Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone.

Authors:  S R Hanson; L A Harker
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

Review 4.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

5.  Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality.

Authors:  Ruchika Goel; Paul M Ness; Clifford M Takemoto; Lakshmanan Krishnamurti; Karen E King; Aaron A R Tobian
Journal:  Blood       Date:  2015-01-14       Impact factor: 22.113

6.  Skin necrosis induced by streptokinase.

Authors:  J Penswick; A L Wright
Journal:  BMJ       Date:  1994-08-06

Review 7.  Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclin.

Authors:  S Moncada
Journal:  Br J Pharmacol       Date:  1982-05       Impact factor: 8.739

Review 8.  Heparin-induced thrombocytopenia: present and future.

Authors:  Adam Cuker
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

9.  Heparin-induced thrombocytopenia, thrombosis, and hemorrhage.

Authors:  D Silver; D N Kapsch; E K Tsoi
Journal:  Ann Surg       Date:  1983-09       Impact factor: 12.969

10.  Porcine heparin increases postoperative bleeding in cardiopulmonary bypass patients.

Authors:  L I Iverson; F G Duhaylongsod; J N Young; R R Ecker; C L Ennix; R L Moretti; M Farrar; R Hayes; J Lee; I A May
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.